This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clovis Oncology Dirección

Dirección controles de criterios 3/4

Información clave

Patrick Mahaffy

Chief Executive Officer (CEO)

US$2.6m

Compensación total

Porcentaje del salario del CEO	28.0%
Permanencia del CEO	13.9yrs
Participación del CEO	0.7%
Permanencia media de la dirección	7.1yrs
Promedio de permanencia en la Junta Directiva	13.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Patrick Mahaffy en comparación con los beneficios de Clovis Oncology?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2022	n/a	n/a	-US$252m
Jun 30 2022	n/a	n/a	-US$263m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$3m	US$739k	-US$265m
Sep 30 2021	n/a	n/a	-US$299m
Jun 30 2021	n/a	n/a	-US$310m
Mar 31 2021	n/a	n/a	-US$336m
Dec 31 2020	US$3m	US$721k	-US$369m
Sep 30 2020	n/a	n/a	-US$370m
Jun 30 2020	n/a	n/a	-US$385m
Mar 31 2020	n/a	n/a	-US$413m
Dec 31 2019	US$7m	US$719k	-US$400m
Sep 30 2019	n/a	n/a	-US$400m
Jun 30 2019	n/a	n/a	-US$396m
Mar 31 2019	n/a	n/a	-US$377m
Dec 31 2018	US$6m	US$689k	-US$368m
Sep 30 2018	n/a	n/a	-US$321m
Jun 30 2018	n/a	n/a	-US$291m
Mar 31 2018	n/a	n/a	-US$366m
Dec 31 2017	US$9m	US$636k	-US$346m
Sep 30 2017	n/a	n/a	-US$365m
Jun 30 2017	n/a	n/a	-US$370m
Mar 31 2017	n/a	n/a	-US$324m
Dec 31 2016	US$789k	US$224k	-US$349m

Compensación vs. Mercado: La compensación total de Patrick($USD2.64M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD474.54K).

Compensación vs. Ingresos: La compensación de Patrick ha sido consistente con los resultados de la empresa en el último año.

CEO

Patrick Mahaffy (59 yo)

13.9yrs

Permanencia

US$2,639,083

Compensación

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Patrick Mahaffy	Co-Founder	13.9yrs	US$2.64m	0.67% € 85.6k
Daniel Muehl	Executive VP & CFO	7yrs	US$1.19m	0.072% € 9.2k
Paul Gross	Executive VP	7.2yrs	US$1.20m	0.068% € 8.7k
Lindsey Rolfe	Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer	7.6yrs	US$1.24m	0.078% € 10.0k
Thomas Harding	Executive VP & Chief Scientific Officer	3.4yrs	sin datos	sin datos
Ann Bozeman	Executive Vice President of Human Resources	6.5yrs	sin datos	sin datos

7.1yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de C6O es experimentado (7.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Patrick Mahaffy	Co-Founder	13.9yrs	US$2.64m	0.67% € 85.6k
Paul Klingenstein	Independent Director	13.9yrs	US$260.00k	0.041% € 5.2k
Brian Atwood	Independent Director	14.2yrs	US$270.00k	0.040% € 5.1k
Edward McKinley	Independent Director	14.2yrs	US$270.00k	0.17% € 22.1k
James Blair	Independent Director	14.2yrs	US$270.00k	0.044% € 5.6k
Ginger Graham	Independent Chairman	10.2yrs	US$287.50k	0% € 0
Thorlef Spickschen	Independent Director	14.2yrs	US$257.50k	0.040% € 5.1k
Ronit Simantov	Director	1.7yrs	US$375.21k	sin datos
Keith Flaherty	Independent Director	10.2yrs	US$259.58k	0% € 0
Richard Fair	Independent Director	4.4yrs	US$257.50k	0% € 0
Robert Azelby	Independent Director	4.4yrs	US$255.00k	0% € 0

13.9yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de C6O son experimentados ( 13.9 años antigüedad media).

This company listing is no longer active

Clovis Oncology Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Now 20% undervalued after recent price drop

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Revenue beats expectations

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €8.10

New 90-day high: €4.77

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.78

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad